Genomictree Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Sung-Whan An

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	15.5%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	geen gegevens

Recente managementupdates

Geen updates

Recent updates

What You Need To Know About Genomictree Inc.'s (KOSDAQ:228760) Investor Composition

Feb 11

CEO

Sung-Whan An (63 yo)

no data

Tenure

Dr. Sungwhan An, Ph D., serves as Chief Executive Officer and President of Genomictree, Inc. Dr. An was a postdoctoral fellow in the Standford University School of Medicine from 1999 to 2000. He earned his...

Genomictree Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

Recent updates

New major risk - Financial data availability

Full year 2023 earnings released: ₩391 loss per share (vs ₩316 loss in FY 2022)

New major risk - Share price stability

New major risk - Revenue and earnings growth

New major risk - Share price stability

New major risk - Share price stability

Genomictree Inc. announced that it has received KRW 5.00000105 billion in funding from ORION Holdings Corp.

Genomictree Inc. (KOSDAQ:A228760) agreed to acquire 4.8% stake in optoLANE Technologies Inc for KRW 5 billion.

Genomictree Inc. announced that it has received KRW 59.9999768 billion in funding from a group of investors

Genomictree Inc. announced that it expects to receive KRW 59.9999768 billion in funding from a group of investors

Full year 2020 earnings released: ₩590 loss per share (vs ₩533 loss in FY 2019)

New 90-day low: ₩12,150

What You Need To Know About Genomictree Inc.'s (KOSDAQ:228760) Investor Composition

New 90-day low: ₩13,750

New 90-day low: ₩13,900

New 90-day low: ₩16,250

New 90-day high: ₩19,300

CEO

Tenure